Swiss pharmaceutical giant Roche has secured European approval for a blood test designed to detect and rule out Alzheimer's disease, marking a potential shift in how the condition is diagnosed across the continent. The test, named Elecsys pTau217, received the CE Mark on Tuesday, confirming its safety and performance for use in the European Union and the wider European Economic Area.
Developed in collaboration with Eli Lilly and Company, the test measures levels of the pTau217 protein in the blood. Elevated levels are a strong indicator that amyloid plaques—abnormal protein deposits linked to Alzheimer's—are likely present in the brain. A negative result, conversely, can help rule out the disease, reducing the need for more invasive procedures.
Alzheimer's is the most common cause of dementia, accounting for 60 to 80 percent of cases. In the EU, the prevalence of dementia among people over 60 rose from 5.9 million in 2000 to approximately 9.1 million in 2018, according to the OECD. Projections suggest that number could reach 13.4 million by 2030 and 18.7 million by 2050, underscoring the urgency for better diagnostic tools.
A Simpler Path to Diagnosis
Current diagnostic methods for Alzheimer's often involve costly and invasive procedures such as lumbar punctures or PET scans, which are not widely available in primary care settings. The Elecsys pTau217 test is designed for use in both primary and secondary care, allowing general practitioners to refer patients to specialists with preliminary data that could accelerate the diagnostic process.
“The launch of pTau217 marks a significant step in providing a simple, blood-based tool to diagnose Alzheimer's much earlier in the patient journey,” said Matt Sause, CEO of Roche Diagnostics. He noted that many patients currently face a long and difficult path to diagnosis, often relying on specialised care and expensive procedures. “By bringing this advanced test into routine care, we are helping physicians to support patients and families with an earlier assessment that is critical for timely intervention, while reducing pressure on healthcare systems,” Sause added.
Carole Ho, executive vice president of Eli Lilly and Company and president of Lilly Neuroscience, emphasised the human impact: “For millions of families navigating the uncertainty of Alzheimer’s, a timely diagnosis is the first and most critical step toward meaningful care.”
The approval comes amid growing interest in early detection and intervention for Alzheimer's, particularly as new treatments emerge that may be more effective when administered early. The test's availability in Europe could also alleviate strain on healthcare systems by reducing the need for specialised diagnostic procedures.
Roche, headquartered in Basel, is one of several European companies investing in Alzheimer's diagnostics. The test's approval also highlights the role of cross-Atlantic collaboration, with Eli Lilly, based in Indianapolis, contributing to its development. For European patients, the test offers a less invasive option that could be integrated into routine blood work, potentially making screening more accessible.
While the test is a significant advancement, experts caution that it is not a standalone diagnostic tool. Positive results should be confirmed through further evaluation, and the test is intended to aid, not replace, clinical judgment. Nonetheless, for the millions of Europeans affected by Alzheimer's—either directly or as caregivers—the approval represents a tangible step toward earlier and more accurate diagnosis.
